Vivimed Labs Limited vs Zydus Lifesciences Limited

A side-by-side comparison of Vivimed Labs Limited (VIVIMEDLAB) and Zydus Lifesciences Limited (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Zydus Lifesciences Limited leads VIVIMEDLAB vs ZYDUSLIFE on 9 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability13
  • Growth01
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

-0.30
P/E ratio
22.42
-0.21
P/B ratio
4.11
0.00%
Dividend yield
0.09%
₹-21.28
EPS
₹50.09

Profitability

ZYDUSLIFE takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

90.88%
Return on equity
18.59%
-91.60%
Return on capital
18.07%
-7.21%
EBITDA margin
31.22%
-250.59%
Net margin
18.87%

Growth

ZYDUSLIFE takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-22.27%
Revenue CAGR (3Y)
16.35%
—
Profit CAGR (3Y) even
34.80%

Size & financial health

ZYDUSLIFE takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹54 Cr
Market cap
₹1.12L Cr
₹70 Cr
Revenue
₹27,148 Cr
₹-175 Cr
Net profit
₹5,124 Cr
0.00
Debt / equity
0.46
Vivimed Labs Limited
  • + []
  • − ["The company has delivered a poor sales growth of -39.5% over past five years.", "Company reported a net loss of ₹175 Cr in its latest financial year."]
Zydus Lifesciences Limited
  • + ["Company has delivered good profit growth of 18.6% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 20.9%"]
  • − []
Vivimed Labs Limited full analysis Zydus Lifesciences Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.